![No Picture](https://etffocus.com/wp-content/themes/mh-magazine/images/placeholder-medium.png)
2018’s Top Performing ETF Is Risky As Heck, But It Looks Like A Winner
I originally profiled the Loncar Cancer Immunotherapy ETF (CNCR) around two years ago. My general opinion at the time was that the immunotherapy category had great potential to turn into a blockbuster market, but CNCR wasn’t necessarily […]